Contact: Dan Lamb
+1 440-420-0987

MENTOR, OHIO – September 28, 2021 – STERIS today announced a new partnership with H+E Pharma, a Stuttgart, Germany-based engineering company. Together, the two companies will design, install and maintain end-to-end, turnkey clean utility water systems for life science pharmaceutical and biotechnology applications in the European market.

For decades, STERIS Finn-Aqua™ Multiple-Effect Water Stills (MWSs) for creation of Water for Injection (WFI) and Pure Steam Generators (PSGs) for pure steam have been the standard for innovation and efficient and reliable production of process utilities.

“We know that our Customers want an end-to-end, turnkey clean utility water system,” said Steve Schultz, Vice President, Global Accounts, STERIS Life Sciences. “We can now provide our broad portfolio of Finn-Aqua® products, alongside H+E’s engineering expertise to offer pre- and post-treatment Purified Water (PW) and WFI systems that use an environmentally sustainable design and provide the lowest total cost of ownership throughout the lifecycle of the system.”

As an added benefit, STERIS can serve as the single point of contact to deliver the turnkey solution, simplifying the engineering, design, build and installation process for a project, as well as post-project maintenance.


STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit For more information about STERIS pharmaceutical and laboratory technologies, please visit

About H+E Pharma

H+E pharma is a pharmaceutical engineering company dedicated to providing purified water system solutions for pharmaceutical clients around the world.


This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," “new,” “advanced,” and “best available,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims, technology advances, and changes in government regulations or the application or interpretation thereof. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or application; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions, affect the production and marketing of existing products, or otherwise affect product performance; or (c)uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other technical literature.